DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the provision of inpatient dialysis services and related laboratory services; and transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Dialysis Dynamics | DaVita navigates volume challenges while maintaining financial resilience, beating earnings expectations despite headwinds in treatment growth |
Strategic Diversification | Explore DaVita's success in phosphate binders and international operations, offsetting core business pressures and opening avenues for expansion |
Reimbursement Outlook | CMS proposes a +1.9% rate update for 2026, providing stability to DaVita's revenue projections amid a complex healthcare reimbursement landscape |
Analyst Perspectives | Barclays Capital sets a $169 price target, while DaVita's conservative guidance approach may position the company for potential upside surprises |
Metrics to compare | DVA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDVAPeersSector | |
---|---|---|---|---|
P/E Ratio | 11.8x | −0.1x | −0.5x | |
PEG Ratio | 1.35 | 0.01 | 0.00 | |
Price/Book | −26.6x | 0.8x | 2.6x | |
Price / LTM Sales | 0.7x | 0.8x | 3.3x | |
Upside (Analyst Target) | 8.2% | 42.0% | 38.7% | |
Fair Value Upside | Unlock | 18.6% | 5.2% | Unlock |